Matches in SemOpenAlex for { <https://semopenalex.org/work/W92079400> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W92079400 endingPage "6" @default.
- W92079400 startingPage "623" @default.
- W92079400 abstract "To investigate the effects of rosiglitazone on serum leptin and insulin resistance (IR) in patients with Type 2 diabetes and to determine the correlation between IR and serum leptin.Thirty-nine Type 2 diabetic patients were given rosiglitazone (4 mg/d) for 12 weeks. The changes of height,weight, fasting plasm glucose (FPG), fasting serum insulin (FINS), serum leptin, hepatic and renal function and serum lipid were examined at the baseline and 12 weeks after the therapy. We used the HOMA model to calculate HOMA-IR as an index of insulin resistance. We also calculated the insulin sensitivity index (ISI). The correlation among the above detected markers was analyzed using multiple regression analysis and partial correlation analysis, respectively.The serum leptin level, FINS, and HOMA-IR were higher (P < 0.01), but ISI was lower in the diabetic patients than those of the normal controls before the treatment. BMI, hepatic function, renal function, and serum lipid level did not significantly change, while FPG, FINS, and HOMA-IR were reduced significantly after the 12-week treatment (P < 0.01). ISI was obviously higher than that before the treatment (P < 0.01). Bivariate analysis showed that the serum leptin was positively correlated with FINS and HOMA-IR (r1 = 0.525, P < 0.01, r2 = 0.391, P < 0.05), but negatively correlated with ISI (r = -0.334, P < 0.05). Multiregressive analysis revealed that the most important factors affecting the leptin in Type 2 diabetes were sex, BMI, TG, FINS, and ISI (R2 = 0.358, P < 0.01).There is close correlation between IR and higher serum leptin level in patients with Type 2 diabetes. Rosiglitazone can reduce FPG level and serum leptin and improve the insulin resistance in patients with Type 2 diabetes." @default.
- W92079400 created "2016-06-24" @default.
- W92079400 creator A5024138459 @default.
- W92079400 creator A5052765696 @default.
- W92079400 creator A5067617942 @default.
- W92079400 creator A5074034142 @default.
- W92079400 date "2004-12-01" @default.
- W92079400 modified "2023-09-24" @default.
- W92079400 title "[Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes]." @default.
- W92079400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16114542" @default.
- W92079400 hasPublicationYear "2004" @default.
- W92079400 type Work @default.
- W92079400 sameAs 92079400 @default.
- W92079400 citedByCount "3" @default.
- W92079400 crossrefType "journal-article" @default.
- W92079400 hasAuthorship W92079400A5024138459 @default.
- W92079400 hasAuthorship W92079400A5052765696 @default.
- W92079400 hasAuthorship W92079400A5067617942 @default.
- W92079400 hasAuthorship W92079400A5074034142 @default.
- W92079400 hasConcept C126322002 @default.
- W92079400 hasConcept C134018914 @default.
- W92079400 hasConcept C159641895 @default.
- W92079400 hasConcept C2777180221 @default.
- W92079400 hasConcept C2777391703 @default.
- W92079400 hasConcept C2778270857 @default.
- W92079400 hasConcept C2779306644 @default.
- W92079400 hasConcept C2780152017 @default.
- W92079400 hasConcept C2780613262 @default.
- W92079400 hasConcept C511355011 @default.
- W92079400 hasConcept C555293320 @default.
- W92079400 hasConcept C71924100 @default.
- W92079400 hasConceptScore W92079400C126322002 @default.
- W92079400 hasConceptScore W92079400C134018914 @default.
- W92079400 hasConceptScore W92079400C159641895 @default.
- W92079400 hasConceptScore W92079400C2777180221 @default.
- W92079400 hasConceptScore W92079400C2777391703 @default.
- W92079400 hasConceptScore W92079400C2778270857 @default.
- W92079400 hasConceptScore W92079400C2779306644 @default.
- W92079400 hasConceptScore W92079400C2780152017 @default.
- W92079400 hasConceptScore W92079400C2780613262 @default.
- W92079400 hasConceptScore W92079400C511355011 @default.
- W92079400 hasConceptScore W92079400C555293320 @default.
- W92079400 hasConceptScore W92079400C71924100 @default.
- W92079400 hasIssue "6" @default.
- W92079400 hasLocation W920794001 @default.
- W92079400 hasOpenAccess W92079400 @default.
- W92079400 hasPrimaryLocation W920794001 @default.
- W92079400 hasRelatedWork W2350211517 @default.
- W92079400 hasRelatedWork W2350630869 @default.
- W92079400 hasRelatedWork W2354214543 @default.
- W92079400 hasRelatedWork W2356383454 @default.
- W92079400 hasRelatedWork W2356417166 @default.
- W92079400 hasRelatedWork W2358718984 @default.
- W92079400 hasRelatedWork W2359226059 @default.
- W92079400 hasRelatedWork W2359976094 @default.
- W92079400 hasRelatedWork W2360049851 @default.
- W92079400 hasRelatedWork W2361269091 @default.
- W92079400 hasRelatedWork W2361780603 @default.
- W92079400 hasRelatedWork W2378369354 @default.
- W92079400 hasRelatedWork W2380805472 @default.
- W92079400 hasRelatedWork W2381306290 @default.
- W92079400 hasRelatedWork W2385803700 @default.
- W92079400 hasRelatedWork W2385892144 @default.
- W92079400 hasRelatedWork W2395379362 @default.
- W92079400 hasRelatedWork W2743962443 @default.
- W92079400 hasRelatedWork W3101982090 @default.
- W92079400 hasRelatedWork W46301430 @default.
- W92079400 hasVolume "29" @default.
- W92079400 isParatext "false" @default.
- W92079400 isRetracted "false" @default.
- W92079400 magId "92079400" @default.
- W92079400 workType "article" @default.